Patrick Brassil
Theravance Biopharma (United States)(US)
Publications by Year
Research Areas
Pharmacogenetics and Drug Metabolism, Cancer therapeutics and mechanisms, Cancer-related Molecular Pathways, Drug Transport and Resistance Mechanisms, DNA Repair Mechanisms
Most-Cited Works
- → BMS-345541 Is a Highly Selective Inhibitor of IκB Kinase That Binds at an Allosteric Site of the Enzyme and Blocks NF-κB-dependent Transcription in Mice(2003)538 cited
- → Discovery of a 1H-Benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) Inhibitor of Insulin-like Growth Factor I Receptor Kinase with in Vivo Antitumor Activity(2005)134 cited
- → Novel N-Linked Aminopiperidine Inhibitors of Bacterial Topoisomerase Type II: Broad-Spectrum Antibacterial Agents with Reduced hERG Activity(2011)101 cited
- → Novel N-Linked Aminopiperidine Inhibitors of Bacterial Topoisomerase Type II with Reduced pKa: Antibacterial Agents with an Improved Safety Profile(2012)89 cited
- → Evaluation of Multiple in Vitro Systems for Assessment of CYP3A4 Induction in Drug Discovery: Human Hepatocytes, Pregnane X Receptor Reporter Gene, and Fa2N-4 and HepaRG Cells(2009)88 cited
- → Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme(2020)82 cited
- → Biotransformation and bioactivation reactions of alicyclic amines in drug molecules(2014)79 cited
- → Discovery of Checkpoint Kinase Inhibitor (S)-5-(3-Fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by Structure-Based Design and Optimization of Thiophenecarboxamide Ureas(2012)67 cited
- → Reaction Phenotyping: Current Industry Efforts to Identify Enzymes Responsible for Metabolizing Drug Candidates(2008)62 cited
- → The right compound in the right assay at the right time: an integrated discovery DMPK strategy(2012)60 cited